Assoc. Prof.Cengiz Dibekoğlu, MD

General Surgeon

Laparoscopic · Robotic · Oncologic Surgery

Conditions/Oncologic surgery

GIST & NET

GIST and Neuroendocrine Tumors

Pathology-driven rare tumors

GIST and NET are not “stomach cancer packages.”

Gastrointestinal stromal tumors (GIST) and neuroendocrine tumors (NET) need pathology, mutation or grade data, and organ-specific planning. They are not managed with a generic gastric-adenocarcinoma checklist. Selected small, low-risk gastric GIST may be surveilled; PDGFRA D842V changes tyrosine-kinase expectations including imatinib resistance. NET versus neuroendocrine carcinoma (NEC) separation is critical — biology and urgency differ. Surgery, TKIs, somatostatin analogs, and peptide-receptor therapies enter only after the report answers the right questions.

GIST and Neuroendocrine Tumors · educational illustration

Educational figures

Tap a figure to enlarge. These English illustrations mirror the Turkish hub gallery for this condition.

  • GIST
  • NET
  • Diagnosis
  • Treatment

  • Pathology first

    Do not lock major therapy without the report.

  • GIST mutations

    PDGFRA D842V changes TKI expectations.

  • NET vs NEC

    Different biology and urgency.

  • Selective surveillance

    Only for selected small low-risk gastric GIST.

Key points for patients

  • GIST surveillance limits
    Tap for details · key note inside

    Surveillance is limited to selected small, especially gastric, non–high-risk lesions. Size, site, and mitotic features decide.

  • Mutation-aware TKI talk
    Tap for details · key note inside
    NoteD842V is not a standard imatinib success story.

    KIT and PDGFRA context matter. Assuming imatinib works for PDGFRA D842V is a planning error.

  • NET localization and grade
    Tap for details

    Grade, Ki-67, organ, size, and behavior individualize care for localized G1–G2 disease.

  • NET versus NEC
    Tap for details · key note inside

    If the report does not clearly separate NET from NEC, therapy should not be locked. NEC behaves differently and often more urgently.

  • Surgery still has a role
    Tap for details

    Resectable primary disease and selected metastases are discussed with mutation/grade context — not postponed forever for “rare tumor mystique.”

Patient journey

In this hub — follow the pathway step by step. Full Turkish illustrated pages remain linked from each chapter.

Oncologic surgery4 chapters

Appointment / info

Pathology with IHC and mutation details is the most useful document you can bring.

+90 542 725 50 70WhatsAppTumor boardFull Turkish hub →

Educational information only; not a substitute for clinical evaluation.

Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · English patient-education hub.

AppointmentWhatsAppMessageTumor boardRequest